Drug intelligence / Profile preview

prednisone + sodium liothyronine

Development stage
Unknown
Lead developer
Pfizer
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination drug consisting of prednisone, a synthetic glucocorticoid corticosteroid, and sodium liothyronine (liothyronine sodium), a synthetic form of the thyroid hormone triiodothyronine (T3). Prednisone acts primarily as an anti-inflammatory and immunosuppressive agent by binding to the glucocorticoid receptor, modulating gene expression, and suppressing immune responses. Sodium liothyronine replaces or supplements endogenous T3 in patients with hypothyroidism or other conditions requiring increased thyroid hormone activity. The combination may be used in clinical scenarios where both anti-inflammatory/immunosuppressive effects and rapid thyroid hormone replacement are needed—such as myxedema coma or certain diagnostic procedures—though this specific fixed-dose combination is not widely marketed under a unique brand name. Both drugs have distinct mechanisms but can interact pharmacologically; for example, corticosteroids like prednisone can decrease levels of thyroxine-binding globulin, affecting circulating thyroid hormones[1][5][9].

02

Targets

GR (Glucocorticoid receptor)THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on prednisone + sodium liothyronine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisone + sodium liothyronine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call